SCHEMBL28079518

SCHEMBL28079518

Nc1ccc(S(=O)(=O)NCCCO)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.66
CYP2D6 P10635 1/20 0.65
CA1 P00915 10/20 0.64
CA2 P00918 10/20 0.64
CA12 O43570 9/20 0.64
CA9 Q16790 9/20 0.64
ALDH1A1 P00352 4/20 0.59
PRMT1 Q99873 1/20 0.57
PKM P14618 3/20 0.56
GAA P10253 1/20 0.56
CA6 P23280 2/20 0.55
CA5A P35218 2/20 0.55
CA7 P43166 2/20 0.55
CA5B Q9Y2D0 2/20 0.55
CA14 Q9ULX7 1/20 0.55
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
MMP13 P45452 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30380602 0.95 CYP2D6 (0.68) CYP3A4CYP2D6CA1CA2CA12
SCHEMBL30380384 0.93 CYP2D6 (0.66) CYP3A4CYP2D6CA1CA2CA12
SCHEMBL2563975 0.89 CYP3A4 (0.70) CYP3A4CYP2D6CA1CA2CA12
SCHEMBL13591295 0.89 CYP2D6 (0.60) CYP3A4CYP2D6CA1CA2CA12
SCHEMBL11682917 0.83 CYP2D6 (0.81) CYP3A4CYP2D6CA1CA2CA12
SCHEMBL11520559 0.83 CYP2D6 (0.81) CYP3A4CYP2D6CA1CA2CA12
SCHEMBL4703731 0.82 CA12 (0.71) CA2CA12CA9ALDH1A1PKM
SCHEMBL5435010 0.82 GAA (0.60) CA1CA2ALDH1A1PKMGAA
SCHEMBL13357765 0.82 CYP3A4 (0.66) CYP3A4CYP2D6CA1CA2CA12
SCHEMBL4085333 0.82 CA12 (0.80) CYP3A4CYP2D6CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136619-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2025-05-01 US disclosed
WO-2023059581-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2023-04-13 WO disclosed
CN-105801582-A Novel dihydro pteridinone derivative, preparing method thereof and application to medicine 合肥工业大学 2016-07-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136619-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE CDK9, AURKB, AURKC CYP3A4 3443/4885CYP2D6 3013/4885CA1 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.